[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 22/29, 1999

Primary HIV-1 ResistanceA New Phase in the Epidemic?

Author Affiliations

Author Affiliation: Departments of Medicine, Biochemistry, and Molecular Pharmacology, Division of Infectious Diseases, Center for Human Virology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa.

JAMA. 1999;282(12):1177-1179. doi:10.1001/jama.282.12.1177

The human immunodeficiency virus type 1 (HIV-1) epidemic, like the virus itself, continues to evolve. Over the last several years, the development of combination antiretroviral chemotherapy, able to suppress plasma virus to undetectable levels in many infected individuals, has led to a profound change in the epidemic, at least in the developed world. Both mortality and morbidity of HIV-1–infected individuals have been decreasing secondary to these combinations of antiretroviral agents, referred to as highly active antiretroviral therapy (HAART).13

First Page Preview View Large
First page PDF preview
First page PDF preview
×